Table 3—

Metabolic parameters during the clamp

PlaceboMetforminRosiglitazone
Before treatment
 Glucose (mmol/l)5.09 ± 0.065.33 ± 0.105.14 ± 0.05
 Insulin (pmol/l)507 ± 24517 ± 26517 ± 54
 FFA (mmol/l)0.17 ± 0.030.16 ± 0.030.15 ± 0.02
 FFA suppression (%)75 ± 565 ± 576 ± 5
 ICR (ml/min)985 ± 46967 ± 54988 ± 89
M (μmol · min−1 · kg−1)17.6 ± 2.120.8 ± 3.621.3 ± 3.6
M/I21.2 ± 2.724.2 ± 3.427.8 ± 6.1
After treatment
 Glucose (mmol/l)5.07 ± 0.065.15 ± 0.055.10 ± 0.04
 Insulin (pmol/l)470 ± 29393 ± 17*431 ± 31*
 FFA (mmol/l)0.13 ± 0.020.12 ± 0.02*0.08 ± 0.01*
 FFA suppression (%)76 ± 377 ± 3*86 ± 3*
 ICR (ml/min)1,080 ± 721,243 ± 66*1,157 ± 93*
M (μmol · min−1 · kg−1)17.2 ± 1.622.6 ± 3.029.4 ± 4.7*§
M/I22.6 ± 2.334.9 ± 4.6*44.0 ± 9.8
  • Data are means ± SEM. Glucose and insulin are plasma levels during the steady-state plasma insulin level of the clamp; M is during the steady state of the clamp. ICR, insulin clearance rate; M/I, M normalized by the steady-state plasma insulin concentration.

  • *

    * P < 0.05 vs. baseline study (Student paired t test in individual groups);

  • P = 0.02 vs. placebo;

  • P < 0.05 vs. placebo;

  • §

    § P < 0.01 vs. placebo and P = 0.05 vs. metformin;

  • P < 0.03 vs. placebo.